Diagnostic value of p504s, ck5/6 and p63 expression level in benign prostatic hyperplasia and prostate cancer
ZHANG Ying1 WANG Xizhe1 ZHOU Lu1 DING Fen′gan2▲
1.Department of Pathology, Huishan People's Hospital of Wuxi City, Jiangsu Province, Wuxi 214011, China;
2.Department of Pathology, Zhongda Hospital Affiliated to Dongnan University, Jiangsu Province, Nanjing 210009, China
Abstract：Objective To study the diagnostic value of alpha methylacyl coenzyme A racemase (p504s), cytokeratin5/6 (ck5/6) and p63 in benign prostatic hyperplasia (BPH) and prostate cancer. Methods Immunohistochemical staining method was used to detect the expression of p504s, ck5/6 and p63 in 120 cases of prostate biopsy specimens that collected in Department of Pathology, Huishan People's Hospital of Wuxi City and Xishan People′s Hospital of Wuxi City from January 2012 to December 2017. In the 120 cases, 70 cases were prostate cancer (prostate cancer group), 50 cases were BPH (BPH group). 65 cases of patients with prostate acinic cell carcinoma were divided into three subgroups according to the Gleason classification standard: ≤6 scores group (20 cases), 7-8 scores group (26 cases) and ≥9 scores group (19 cases). The product of staining intensity and percentage of positive cells was compared among these groups. Statistical software SPSS 15.0 was used to analyze the results. Results The expression rate of p504s in the prostate cancer group was 91.43%, 64.28% (45/70) were strongly positive. Only 5 cases of BPH group were p504s weakly positive, and the expression rate was 10.00%. The positive rate of ck5/6 expression in prostate cancer group was 11.43% (8/70), and all of them were weakly positive. 90.00% (45/50) of BPH group were ck5/6 positive expression, and 84.00% (42/50) were positive expression above medium intensity. The positive rate of p63 expression in prostate cancer group was 8.57% (6/70), and all of them were weakly positive. 92.00% (46/50) of BPH group were p63 positive, and 82.00% (41/50) were positive expression above medium intensity. There was a significant difference in the expression of p504s, ck5/6 and p63 in the two groups (P ＜ 0.05). There was a significant difference in the expression intensity of p504s in ≤6 score group, 7-8 score group and ≥9 score group (P ＜ 0.05). The expression intensity of p504s in 7-8 score group and ≥9 score group were significantly higher than that in ≤6 score group (P ＜ 0.05). The expression intensity of p504s in 7-8 score group and ≥9 score group had no significant difference (P ＞ 0.05). There was no significant difference in the expression intensity of ck5/6 and p63 among three types of benign prostatic hyperplasia tissues, which included partial atrophy of glands, complete atrophy of glands, and hyperplasia of basal cells (P ＞ 0.05). There were 3 cases of ck5/6 deletion, and 2 cases of p63 expression deletion in the glandular partial atrophy. There were 2 cases of ck5/6 expression deletion, and 2 cases of p63 expression deletion in the complete atrophy of glands. Conclusion The expression of p504s is highly expressed in the prostate cancer tissue, while the expression of p63 and ck5/6 is decreased significantly. The expression intensity of p504s is enhanced with the degree increase of Gleason classification. It is suggested that the combined detection of p504s, ck5/6 and p63 has good application value in the diagnosis of prostate cancer and BPH.
[1] Chen WQ，Zheng RS，Baade PD，et al. Cancer statistics in China [J]. Ca Cancer J Clin，2016，66：115-132.
[2] 王伟.前列腺特异性膜抗原为靶标的前列腺癌靶向疗法研究进展[J].中华男科学杂志，2010，16（6）：547-551.
[3] Ben JA，Bouraoui Y，Oueslati R. Insight into the heterogeneity of prostate cancer through PSA-PSMA prostate clones：mechanisms and consequences [J]. Histol Histopathol，2014， 29（10）：1263-1280.
[4] 孔凡雷，方建华，包凌云，等.超声造影引导减针在前列腺癌穿刺活检的应用[J].中国超声医学杂志，2015，31（12）：1114-1116.
[5] 吴秉铨.免疫组织化学病理诊断[M].北京：北京科学技术出版社，2007.
[6] Lloyd MD，Yevglevskis M，Lee GL，et al. α-Methylacyl-CoA racemase（AMACR）：Metabolic enzyme，drug metabolizer and cancer marker P504S [J]. Prog Lipid Res，2013， 52（2）：220-230.
[7] Xu J，Stolk JA，Zhang X，et al. Identification of differentially expressed genes in human prostate cancer using subtraction and microarray [J]. Cancer Res，2000，60（6）：1677-1682.
[8] 陈真伟，施红旗，应李雄，等.P504s在胰腺实性假乳头瘤和胰腺神经内分泌肿瘤鉴别诊断中的价值[J].中华病理学杂志，2015，44（5）：320-322.
[9] 陆勤平，黄文斌，刘家祥，等.AMACR/p504S在胃癌中的表达及其临床意义[J].实用医学杂志，2012，28（16）：2682-2684.
[10] Jiang Z，Woda BA，Wu CL，et al. Discovery and clinical application of a novel prostate cancer marker： alpha-methylacyl CoA racemase（P504S）[J]. Am J Clin Pathol，2004，122（2）：275-289.
[11] Murray NP，Calaf GM，Badinez L，et al. P504S expressing circulating prostate cells as a marker for prostate cancer [J]. Oncol Rep，2010，24（3）：687-692.
[12] Zeng XJ，Bi XC，Dai QS，et al. Effects of PPAR-gamma on the proliferation and glycolysis metabolism of prostate cancer cells [J]. Zhonghua Nan Ke Xue，2012，18（8）：692-696.
[13] Mubiru JN，Shen-Ong GL，Valente AJ，et al. Alternative spliced variants of the alpha-methylacyl-CoA racemase， gene and their expression in prostate cancer [J]. Gene，2004，327（1）：89-98.
[14] 李艳菊，张春莉，杨彦玲，等.TMPRSS2-ERG、P504S、P63和34βE12在前列腺癌中表达与临床意义[J].延安大学学报，2017，15（2）：22-24.
[15] Jiang N，Zhu S，Chen J，et al. A-methylacyl-CoA racemase（AMACR）and prostate-cancer risk：a meta-analysis of 4，385 participants [J]. PLoS One，2013，8（10）：e74386.
[16] Fichtenbaum EJ，Jr MW，Zynger DL. CK5，CK5/6，and double-stains CK7/CK5 and p53/CK5 discriminate in situ vs invasive urothelial cancer in the prostate [J]. Am J Clin Pathol，2012，138（2）：190-197.
[17] 董永学.免疫组化在前列腺穿刺小标本活检中的应用价值[J].现代诊断与治疗，2015，26（16）：3755-3756.
[18] 林秋兰，林竞，赵丽华，等.前列腺穿刺活检临床病理及免疫组化诊断前列腺癌的研究[J].现代中西医结合杂志，2014，23（6）：596-599，603.
[19] 何正华.前列腺穿刺组织病理诊断分析[J].心理医生，2017，23（33）：143-144.
[20] Huang Y，Hamana T，Liu J，et al. Prostate Sphere-forming Stem Cells Are Derived from the P63-expressing Basal Compartment [J]. Journal of Biological Chemistry，2015，290（29）：17745-17752.
[21] 翁亚菡.前列腺穿刺标本行P504s、P63、CK34βE12免疫组化检测的临床价值分析[J].中国实用医刊，2016， 12（1）：69-70.
2018, Vol. 15 
京公网安备 11010502046598号